Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages 1-5

  Tosi, Patrizia ^a   Gamberi, Barbara ^b   Castagnari, Barbara ^c   Molinari, Anna Lia ^a   Savini, Paolo ^d   Ceccolini, Michela ^e   Tani, Monica ^c   Merli, Anna ^a   Imola, Manuela ^a   Mianulli, Anna Maria ^a   Cellini, Claudia ^c   Tomassetti, Simona ^a   Merli, Francesco ^b   Fattori, Pierpaolo ^e   Zaccaria, Alfonso ^e  

^a Infermi Hospital   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^d Faenza Hospital   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CREATININE; DEXAMETHASONE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE;

AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMORBIDITY; CREATININE CLEARANCE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; ELDERLY CARE; FEMALE; HEMODIALYSIS; HUMAN; INFECTION; ITALY; KIDNEY FAILURE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ADVANCED CANCER; AGING; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEALTH STATUS; KIDNEY DISEASE; KIDNEY FUNCTION; PROTEINURIA; REFRACTORY PERIOD; SURVIVAL TIME;

EID: 84890516588     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2013.037     Document Type: Article

References (23)

1. Kyle RA, Rajkumar SV Multiple myeloma. N Engl J Med 2004; 351:1806-1873. http://dx.doi.org/10.1056/NEJMra041875 PMid:15509819
2. Kumar SK, Rajkumar SV, Dispenzieri A Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520. http://dx.doi.org/10.1182/blood-2007-10-116129 PMid:17975015 PMCid:2254544
3. Kumar SK, Lee JH, Lahuerta JJ Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, San Miguel J, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG Risk of progression and survival in multiple myeloma relapsing after therapy with ImiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-157. http://dx.doi.org/10.1038/leu.2011.196 PMid:21799510
4. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International myeloma working group. J Clin Oncol 2010; 28:4976-4984. http://dx.doi.org/10.1200/JCO.2010.30.8791 PMid:20956629
5. Tosi P, Zamagni E, Tacchetti P Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, Cavo M Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency Biol Blood Marrow Transplant 2010;16:1115-1121
6. Chanan-Khan AA, Kaufman JL, Metha JRichardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-2606. http://dx.doi.org/10.1182/blood-2006-09-046409 PMid:17138816
7. Chen N, Lau H, Kong L Kumar G, Zeldis JB, Knight R, Laskin OL Pharmacokinetics of lenalidomide in subjects wiyh various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466-1475. http://dx.doi.org/10.1177/0091270007309563 PMid:17954615
8. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007;138:640-643. http://dx.doi.org/10.1111/j.1365-2141.2007.06698.x PMid:17686058
9. Chen C, Reece DE, Siegel D Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson PG, Matous J, Kumar S, Bahlis NJ, Alsima M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V Expanded safety experience with with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164-170. http://dx.doi.org/10.1111/j.1365-2141.2009.07728.x PMid:19545290 PMCid:2728892
10. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Cancer. 2010;116:3807-3814. http://dx.doi.org/10.1002/cncr.25139 PMid:20564094 PMCid:2970911
11. Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H Lenalidomide in combination with dexameyhasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011; 90:429-43. http://dx.doi.org/10.1007/s00277-010-1080-4 PMid:20857112
12. Ludwig H, Zojer N Renal recovery with lenalidomide in a patient with bortezomib-resistant myeloma. Nat Rev Oncol 2010;7:289-294. http://dx.doi.org/10.1038/nrclinonc.2010.31 PMid:20351701
13. de la Rubia J, Roig M, Ibanez A, Garcia I, Vera JA, Aguilar C, Del Campo R, Gonzales N, Martinez R, Palomera L, Picon I, Rodriguez JN, Sanz M Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol 2010; 85:363-365. http://dx.doi.org/10.1111/j.1600-0609.2010.01500.x PMid:20662900
14. Oehrlein K, Langer C, Sturm I, Ponisch W, Hahn-Ast C, Kuhn S, Weisel KC Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 german centers. Clin Lymphoma, myeloma and leukemia 2012; 12:191-196.
15. Dimopoulos MA, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treat Rev 2012;38:1012-1019. http://dx.doi.org/10.1016/j.ctrv.2012.02.009 PMid:22609463
16. Dimopoulos MA, Palumbo A, Attal M, Beksac M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, Leal Da Costa F, Ludwig H, Mellqvist UH,m Morgan GJ, San Miguel JF, Zweegman S, Sonneveld P Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25749-760.
17. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K,Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadoro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma Leukemia. 2006;20:1467-1473. http://dx.doi.org/10.1038/sj.leu.2404284 PMid:16855634
18. Kyle RA, Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3-9. http://dx.doi.org/10.1038/leu.2008.291 PMid:18971951 PMCid:2627786
19. Dimopoulos MA, Roussou M, Gkotzamanidou Nikitas N, Psimenou E, Mparmaparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma Leukemia 2013;27:423-429. http://dx.doi.org/10.1038/leu.2012.182 PMid:22763386
20. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellman A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyi M, Patin J, Zeldis JB, Knight RD, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123-2132. http://dx.doi.org/10.1056/NEJMoa070594 PMid:18032762
21. Specter R, Sanchorawala V, Seldin DC Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM Kidney disfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011; 26:881-886. http://dx.doi.org/10.1093/ndt/gfq482 PMid:20693160 PMCid:3108346
22. Sarkozi R, Perco P, Hochegger K Enrich J, Wiesinger M, Pirklbauer M, Eder S, Rudnicki M, Rosenkranz AR, Mayer B, Schramek H Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327:645-656. http://dx.doi.org/10.1124/jpet.108.142604 PMid:18776064
23. Palumbo A, Bringhen S, Ludwig HDimopoulos MA, Bladé J, Mateos MV, Rosi-ol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118:4519-4529. http://dx.doi.org/10.1182/blood-2011-06-358812 PMid:21841166